Biotoxtech Co., Ltd. Overview
Biotoxtech is a Korean preclinical contract research organisation (CRO). It generates the GLP safety and efficacy data that drug, chemical, cosmetic, food and agrochemical developers must submit to regulators before human testing or market approval. Founded in 2000 by veterinary toxicologist Kang Jong-koo, it describes itself as Korea's largest private toxicology testing house. It was the first Korean private nonclinical lab to pass a US FDA GLP inspection (January 2015). It is a single-segment business with two operating platforms:
-
The parent company runs rodent and non-rodent toxicology, safety pharmacology, genotoxicity, ecotoxicology and bioanalysis from its Ochang campus.
-
The subsidiary KPrime Research runs a large private non-human primate (NHP) facility at Osong, built in 2022.
After two years of heavy losses (FY2023–FY2024), the group is in a backlog-led recovery. H1 2026 consolidated revenue rose 26% and the subsidiary posted its first quarterly operating profit. However, leverage, negative working capital and a minority-interest deficit at the subsidiary remain the central investment risks.
What the company does. Biotoxtech sells contract nonclinical studies. A sponsor (a pharmaceutical company, biotech, chemical producer or cosmetics/food firm) commissions a study protocol. Biotoxtech conducts the in-life phase in laboratory animals or in vitro systems, analyses samples, and delivers a GLP-compliant final report. The report then goes into regulatory dossiers such as an IND, NDA/BLA, chemical registration or functional-ingredient approval.
Data vendors summarise the company's business as follows:
-
Safety evaluation of medical products, cosmetics, food and chemicals.
-
Efficacy testing and material screening.
-
Consulting on nonclinical test strategy.
The safety-evaluation catalogue spans:
-
General toxicity, carcinogenicity and local toxicity
-
Reproductive/developmental toxicity, genotoxicity and immunotoxicity
-
Safety pharmacology
-
Aquatic ecotoxicology
-
Histopathology/clinical pathology
-
Alternative (non-animal) test methods
Company's own description (paraphrased from company materials). The company presents itself as holding the largest number of GLP-certified test categories and the most completed GLP studies among Korean nonclinical CROs. It cites hundreds of data submissions to US, Japanese and European regulators on behalf of domestic and overseas clients. It highlights:
-
The 2015 FDA GLP inspection.
-
Its selection as Korea's representative CRO for the November 2010 OECD Mutual Joint Visit GLP inspection.
-
Full AAALAC International accreditation, including being the first private Asian CRO accredited for aquatic (environmental) toxicity.
-
Being first in Korea to be certified for safety pharmacology and for alternative animal-test methods.
It also describes:
-
A bioanalysis joint venture (SBB) formed with Japan's Sumika Chemical Analysis Service, to cover small-molecule, antibody and biologic sample analysis.
-
A leading role in chemical risk and aquatic-toxicity assessment under K-REACH (화평법), Korea's chemical registration law.
Revenue model. Revenue comes from fee-for-service study contracts, often milestone-billed and recognised over the study period. Order intake therefore converts to revenue with a lag of several quarters. Management states this explicitly when discussing its backlog. There is no subscription or licensing revenue of note.
Two non-core income streams appear in the financials:
Investment gains: gains on strategic equity stakes, notably in G2GBIO, contributed KRW 8.0bn of FY2025 pre-tax income.
Laboratory-animal sales: the group lists animal sales within its "total service" offer.
Value-chain position. Biotoxtech sits between drug discovery and Phase 1 clinical trials (the "IND-enabling" stage). It also serves the regulatory-safety requirements of chemicals and consumer products. Its value proposition rests on three things:
Regulatory acceptability: OECD GLP mutual acceptance and FDA inspection history.
Species breadth: rodents, non-rodents, and NHPs via KPrime.
Data packaging: it now offers turn-key packages that include SEND datasets, the FDA's standard electronic format for nonclinical data, needed for FDA filings.
Customer types and end markets.
-
Korean biotech and pharmaceutical companies developing new drugs, biologics, cell and gene therapies, ADCs, ASOs, peptides and vaccines. This is the core base and the source of cyclicality.
-
Overseas biotechs: historically Japan-centric, now diversifying towards the US, Europe and Singapore (Sep 2026 company statement).
-
Chemical companies needing K-REACH registration data.
-
Cosmetics, health-functional-food and agrochemical developers.
-
Government and public R&D programmes. TheVC registry data lists 29 national R&D projects and 52 B2G contracts.
Independent characterisation. Biotoxtech is a sub-scale but credentialed national champion in a market dominated globally by Charles River, Labcorp, Inotiv and the large Chinese CROs. Domestically its main rival for regulatory-grade toxicology is the government-funded Korea Institute of Toxicology (KIT).
Its economics are those of a high-fixed-cost laboratory operator:
-
Gross margin swings violently with utilisation, from 33% in FY2022 to 6% in FY2023.
-
The 2022 NHP build-out roughly doubled the asset base and loaded the group with debt just as Korean biotech funding contracted.
-
The recovery thesis depends on two things: filling the NHP capacity with export-oriented, higher-value biologics work, and converting a record backlog into utilisation.
Strategy
Stated strategic themes (paraphrased from the Feb 2026 "Letter to Shareholders" and 2026 IR communications).
-
2026 as the first year of the earnings turnaround. Management says it completed a structural overhaul through quality improvement and efficiency during the FY2023–FY2024 downturn.
-
Become a global top-tier nonclinical CRO. Leverage FDA GLP inspection history to win US and European biotech work.
-
Full-lifecycle nonclinical "total service." Cover primates, rodents and non-rodents, toxicology and efficacy, bioanalysis and laboratory-animal supply under one group.
-
Move up the value curve into advanced modalities. Build capability in ADC, ASO, peptides, next-generation vaccines and gene therapy, which the company says carry higher average order values and margins.
-
Package and long-duration contracts. Shift from single studies to turn-key multi-study packages with SEND data and multi-year projects. Management says average order size has moved from a few hundred million won to the KRW 1bn+ range.
-
Shareholder-value programme. Buybacks (including cancellation), expanded NDR/IR activity and transparent disclosure.
-
Unlock KPrime's value through an IPO. KPrime has applied for a designated auditor as a formal pre-IPO step.
Strategic initiatives, last 24 months.
Medium-term targets and guidance.
No formal multi-year revenue or margin targets were identified.
ESG/sustainability commitments: no quantified commitments identified. Animal-welfare (AAALAC) and alternative-method (3Rs) activities are the substantive ESG-relevant programmes.
Products & Services
All offerings sit within the single nonclinical CRO segment. Pricing is per study and quoted individually; no list prices are disclosed. Launch years are given only where disclosed.
Parent company (Ochang) — safety evaluation
| Service line | Description and capabilities | Target customer | Notes |
|---|---|---|---|
| General toxicity (single and repeated dose) | Acute to chronic dosing studies in rodents and non-rodents to define target organs and NOAEL | Drug, biologic, chemical and cosmetic developers | Core GLP offering |
| Carcinogenicity | Long-term rodent bioassays | Small-molecule and chemical sponsors | Long-duration, high-backlog studies |
| Local toxicity | Dermal/ocular irritation, sensitisation, injection-site tolerance | Cosmetics, topical and injectable developers | Includes alternative in-vitro methods |
| Reproductive & developmental toxicity | Fertility, embryo-fetal development, pre/postnatal studies | Pharma, agrochemical | — |
| Genotoxicity | Ames, chromosomal aberration, micronucleus and related assays | All new-substance sponsors | Part of SEND-ready packages |
| Immunotoxicity | Immune-function and immunogenicity assessment | Biologics, vaccines | — |
| Safety pharmacology | CNS, respiratory, cardiovascular core battery | Pharma/biotech | Company claims the first Korean certification in this field |
| Aquatic ecotoxicology | Fish, daphnia and algae tests for environmental risk | Chemical companies (K-REACH) | AAALAC-accredited aquatic programme (first private Asian CRO) |
| Histopathology / clinical pathology | Tissue evaluation, haematology, clinical chemistry | All study types | In-house pathology |
| Alternative animal-test methods (NAMs) | Validated in-vitro / non-animal methods | Cosmetics (animal-test restrictions), chemicals | Company claims the first Korean certification; KPrime has a dedicated NAMs task force |
| Chemical risk assessment | Hazard and risk dossiers for K-REACH registration | Chemical manufacturers/importers | Company cites hundreds of assessments per year |
Parent company — efficacy, analytics and data services
| Service line | Description | Target customer |
|---|---|---|
| Efficacy evaluation | Disease-model pharmacology studies (pipeline partners include obesity, diabetes, dementia, prostate cancer and hair-loss programmes under the G2GBIO agreement) | Biotech |
| Toxicokinetics / pharmacokinetics and bioanalysis | Sample analysis for small molecules, antibodies and biologics; historically via the SBB JV with Sumika Chemical Analysis Service | Pharma/biotech |
| Material screening & consulting | Early candidate screening and nonclinical strategy design | Early-stage biotech |
| SEND dataset preparation | CDISC-SEND electronic datasets required for FDA submissions, bundled with general toxicity, safety pharmacology, genotoxicity, TK and bioanalysis as a turn-key package | US-bound sponsors |
| Turn-key IND packages | Multi-study bundles for advanced modalities (ADC, ASO, peptides, next-generation vaccines, gene therapy) | Global biotech; company targets larger, multi-year package contracts |
KPrime Research (Osong) — NHP platform
| Service line | Description | Launch / certification | Target customer |
|---|---|---|---|
| NHP repeated-dose toxicity (GLP) | Primate toxicology for biologics, ADCs and oligonucleotides where rodents are not pharmacologically relevant | GLP certified 2023 | Global and Korean biotech |
| NHP cardiovascular safety pharmacology (GLP) | Telemetry-based cardiovascular safety studies | GLP certified 2025; described as Korea's first primate safety-pharmacology GLP | IND-stage sponsors |
| Liver and heart biopsy services | Serial biopsy sampling in primates | — | Gene/cell therapy, metabolic programmes |
| Ophthalmic special administration | Intravitreal and other ocular dosing | — | Ophthalmology drug developers |
| Immunoassay services | Immunogenicity and biomarker analysis | — | Biologics |
| NHP efficacy & PK studies | Neurodegenerative and other disease models, e.g. the 2022 BioOrchestra MOU | 2022 onward | RNA/CNS developers |
Flagship offerings, by management emphasis:
-
FDA-inspected GLP general toxicity with SEND.
-
NHP GLP toxicology and safety pharmacology at KPrime.
-
Turn-key packages for ADC, ASO and gene-therapy programmes.
Financial Narrative
Source: S&P Global Market Intelligence via StockAnalysis.com, consolidated IFRS, KRW millions, FY ending 31 December. TTM = 12 months to 30 Jun 2026.
Margins and growth
Revenue CAGR FY2021–FY2025: 9.5% (analyst calculation: 47,017 / 32,717 over four years).
TTM to June 2026: revenue KRW 52,476M (+20.9%), gross margin 14.07%, operating margin −8.81%, EBITDA roughly breakeven (KRW −159M), attributable net loss KRW −3,995M.
Commentary.
The FY2023 inflection: FY2023 revenue fell 12.5% while cost of revenue rose 23.8%. Gross margin collapsed from 33% to 6%. Three forces converged:
-
The Korean biotech funding drought hit order intake; management later blamed reduced private and government R&D investment.
-
The new KPrime facility began depreciating and staffing up before revenue arrived.
-
Inventory, mostly laboratory animals and NHPs, built from KRW 4.5bn to KRW 11.9bn ahead of demand.
FY2024: Revenue recovered 26.7%, but cost of revenue grew almost as fast. Operating losses persisted at KRW 8.6bn, and a KRW 3.8bn tax charge (likely deferred-tax-asset write-down; DTA fell from KRW 5.3bn to KRW 1.9bn) deepened the net loss.
FY2025: Gross margin doubled to 12.3% and operating loss narrowed by 31%. Attributable net income turned positive (KRW 1.2bn) only because of an KRW 8.0bn gain on investment sales, most plausibly linked to the G2GBIO stake or other securities. Without that gain, the pre-tax loss would have been about KRW 8.4bn ("EBT excluding unusual items" was KRW −8,371M).
Interest burden: Interest expense rose 6.5x from FY2021 to FY2025, reaching 11.5% of revenue. This is now the single largest drag below EBIT.
SG&A: has been flat at about KRW 8.8bn for three years. Operating leverage on revenue growth should therefore be high.
Balance sheet
30 June 2026 snapshot:
-
Cash and short-term investments KRW 29.3bn.
-
Total debt KRW 68.4bn; net debt KRW 39.1bn.
-
Current liabilities KRW 97.0bn against current assets KRW 52.5bn (working capital KRW −44.4bn).
-
Total equity KRW 22.4bn, of which parent KRW 32.5bn and NCI KRW −10.1bn.
-
Debt/equity 3.05x.
Commentary. The FY2022 balance-sheet step-change reflects KPrime's Osong campus, which doubled PP&E (buildings rose from KRW 22.7bn to KRW 51.2bn). It was funded largely with debt and mezzanine instruments: net debt moved from a KRW 1.1bn net cash position to KRW 18.4bn.
Two features stand out:
Liquidity is structurally tight: IB Tomato (Jan 2026) noted the parent's standalone current ratio exceeds 100%. Consolidating KPrime's short-term borrowings and CBs cuts the ratio by about 45.6 percentage points, to around 60%. KPrime's own cash is insufficient to service its debts, so the parent is the de facto backstop.
"Other current liabilities" are large: KRW 32.9bn at FY2025 and KRW 36.9bn at June 2026. This line likely contains contract liabilities (customer advances on studies) and/or KPrime's CBs. Advances would be a sign of backlog strength rather than financial debt. The split is not publicly disclosed in sources reviewed.
Cash flow
TTM to June 2026: OCF KRW 5.5bn, capex KRW 3.6bn, FCF KRW 1.9bn. Debt issued KRW 14.4bn and repaid KRW 13.8bn (refinancing).
Commentary. Cumulative FCF over FY2021–FY2024 was about KRW −65bn, funded by roughly KRW 76bn of net new debt over FY2021–FY2023. FY2025 was the first year of positive FCF (KRW 4.5bn). Most of the improvement came from working-capital release: inventory fell by KRW 7.5bn as NHP stock was consumed in studies. This is not repeatable at the same scale. The capex cycle is over; maintenance capex is running at about KRW 2–4bn per year. Self-funded deleveraging is therefore possible only once EBITDA turns sustainably positive.
Ratios
Sources: ROE, ROA, ROIC, current/quick ratios, D/E, net debt/equity and asset turnover are from S&P / StockAnalysis. Interest coverage and the working-capital day metrics are analyst calculations from the reported figures. The cash conversion cycle excludes customer advances held in other current liabilities, so the true cash cycle is likely shorter.
Net debt/EBITDA: −0.17x (FY2021) and 6.69x (FY2022). Not meaningful for FY2023–FY2025 because EBITDA was negative. Current June 2026 D/E: 3.05x.
Ratio commentary. All return metrics have been negative since FY2023. Interest coverage has been below 1x since FY2022. The cash conversion cycle peaked above 200 days in FY2024, driven by animal inventory, and has since normalised. The current ratio has deteriorated every year since FY2023; refinancing of short-term bank lines and CBs is therefore the core financial risk.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Location | Ownership |
|---|---|---|---|
Biotoxtech Co., Ltd. (parent) | Rodent/non-rodent toxicology, safety pharmacology, genotoxicity, ecotoxicology, efficacy, bioanalysis, chemical risk assessment | Ochang, Cheongju | Listed |
KPrime Research Co., Ltd. (키프라임리서치) | NHP toxicology, safety pharmacology (cardiovascular telemetry), biopsy services, ophthalmic dosing, immunoassays | Osong, Cheongju | Consolidated subsidiary. Exact stake not publicly disclosed in sources reviewed; a large minority interest exists (see below) |
SBB (JV with Sumika Chemical Analysis Service) | Bioanalysis (TK/PK) | Korea (location not disclosed) | A FY2022 divestiture/discontinued-operation entry may relate to a disposed affiliate (unconfirmed) |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Nonclinical CRO revenue (KRW Mn) | 32,717 | 37,292 | 32,631 | 41,341 | 47,017 |
Nonclinical CRO revenue YoY growth (%) | 23.79 | 13.98 | -12.50 | 26.69 | 13.73 |
Nonclinical CRO operating income (KRW Mn) | 4,632 | 800 | -8,676 | -8,619 | -5,908 |
Nonclinical CRO operating margin (%) | 14.16 | 2.15 | -26.59 | -20.85 | -12.57 |
Share of total revenue (%) | 100 | 100 | 100 | 100 | 100 |
Revenue by Segment (KRW) and Segment Margins & Growth (%)
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Consolidated revenue (KRW 100M) | 208 | 263 |
Consolidated operating income (KRW 100M) | -33 | -20 |
Parent standalone revenue (KRW 100M, H1 2025 derived from +8% growth) | 149 | 161 |
Parent standalone new orders (KRW 100M, H1 2025 derived from +17% growth) | 169 | 198 |
Parent standalone order backlog at period end (KRW 100M, H1 2025 derived from +18% growth) | 369 | 435 |
Kprime Metric Details
| KPrime metric | Value | Period / source |
|---|---|---|
Q2 2026 revenue | KRW 5.8bn | BizWatch, 19 Aug 2026 |
Q2 2026 operating income | KRW 0.4bn (first quarterly profit since founding) | BizWatch, 19 Aug 2026 |
H1 2026 new contracts | KRW 17.2bn, of which >60% from overseas clients | BizWatch / Asia Economy, Aug 2026 |
Implied H1 2026 revenue | ~KRW 10.2bn (consolidated KRW 26.3bn less parent KRW 16.1bn, before intercompany eliminations) | Analyst derivation |
Implied FY2025 revenue | ~KRW 14–14.5bn. Derived from the Feb 2026 USD 2.45M contract (>25% of prior-year revenue) and the Mar 2026 €1.38M contract (16.5% of prior-year revenue) | Analyst derivation |
Combined group backlog at end-June 2026 | KRW 60.7bn (parent KRW 43.5bn + KPrime ~KRW 17.2bn by subtraction) | BizWatch, 19 Aug 2026 |
Growth track record | Orders and revenue grew >100% per year since operations began in 2023 | Company letter, Feb 2026 |
Revenue from US/Europe | ~50% (FY2025) | Company letter, Feb 2026 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Mn) | 32,717 | 37,292 | 32,631 | 41,341 | 47,017 |
Cost of revenue (KRW Mn) | 22,208 | 24,863 | 30,769 | 38,842 | 41,215 |
Gross profit (KRW Mn) | 10,509 | 12,429 | 1,862 | 2,499 | 5,802 |
SG&A (KRW Mn) | 5,362 | 9,319 | 8,773 | 8,810 | 8,765 |
Operating income (KRW Mn) | 4,632 | 800 | -8,676 | -8,619 | -5,908 |
D&A (KRW Mn) | 1,672 | 1,945 | 3,679 | 4,098 | 4,333 |
EBITDA (KRW Mn) | 6,304 | 2,745 | -4,998 | -4,521 | -1,576 |
Interest expense (KRW Mn) | 833 | 2,015 | 3,764 | 5,086 | 5,425 |
Gain on sale of investments (KRW Mn) | 1,846 | 1,472 | 13 | -1,242 | 8,030 |
Pre-tax income (KRW Mn) | 6,485 | -644 | -11,833 | -8,822 | -346 |
Income tax expense (KRW Mn) | -213 | -709 | -2,883 | 3,836 | 1,228 |
Net income to company incl. minorities (KRW Mn) | 6,980 | 1,512 | -8,950 | -12,657 | -1,573 |
Minority interest share of losses (KRW Mn) | 134 | 1,214 | 4,073 | 6,230 | 2,736 |
Net income attributable to parent (KRW Mn) | 7,114 | 2,725 | -4,878 | -6,427 | 1,163 |
EPS basic (KRW) | 486.65 | 186.19 | -316.14 | -405.00 | 74.43 |
EPS diluted (KRW) | 444.28 | 185.86 | -316.14 | -405.00 | 74.43 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth (%) | 23.79 | 13.98 | -12.50 | 26.69 | 13.73 |
Gross margin (%) | 32.12 | 33.33 | 5.71 | 6.04 | 12.34 |
Operating margin (%) | 14.16 | 2.15 | -26.59 | -20.85 | -12.57 |
EBITDA margin (%) | 19.27 | 7.36 | -15.32 | -10.94 | -3.35 |
Net margin, attributable (%) | 21.74 | 7.31 | -14.95 | -15.55 | 2.47 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Mn) | 90,741 | 125,700 | 147,036 | 136,191 | 131,607 |
Cash & equivalents (KRW Mn) | 18,592 | 12,700 | 27,479 | 11,370 | 18,632 |
Cash + short-term investments (KRW Mn) | 28,151 | 30,771 | 41,038 | 32,384 | 28,132 |
Accounts receivable (KRW Mn) | 5,813 | 7,352 | 5,355 | 7,863 | 8,700 |
Inventory (KRW Mn) | 674 | 4,454 | 11,915 | 14,786 | 7,218 |
Property, plant & equipment (KRW Mn) | 25,409 | 58,066 | 58,181 | 56,516 | 55,071 |
Long-term investments (KRW Mn) | 18,373 | 10,130 | 10,689 | 10,320 | 18,902 |
Goodwill & intangibles (KRW Mn) | 1,479 | 1,483 | 1,596 | 1,665 | 1,276 |
Short-term debt incl. current portion of LTD (KRW Mn) | 24,843 | 28,853 | 41,229 | 46,568 | 51,037 |
Long-term debt (KRW Mn) | 1,909 | 20,000 | 20,000 | 16,250 | 11,250 |
Total debt incl. leases (KRW Mn) | 27,049 | 49,140 | 61,591 | 63,049 | 62,500 |
Net debt (KRW Mn) | -1,102 | 18,369 | 20,553 | 30,665 | 34,367 |
Total current assets (KRW Mn) | 37,746 | 49,130 | 64,692 | 58,918 | 48,615 |
Total current liabilities (KRW Mn) | 45,777 | 59,528 | 75,119 | 82,210 | 85,492 |
Working capital (KRW Mn) | -8,031 | -10,398 | -10,426 | -23,292 | -36,877 |
Parent shareholders' equity (KRW Mn) | 41,144 | 44,235 | 51,710 | 40,082 | 40,157 |
Non-controlling interest (KRW Mn) | 706 | 132 | -3,475 | -5,557 | -8,226 |
Total equity (KRW Mn) | 41,849 | 44,367 | 48,235 | 34,525 | 31,931 |
Treasury stock (KRW Mn) | -166 | -166 | -166 | -1,163 | -2,161 |
Book value per share (KRW) | 2,811 | 3,022 | 3,247 | 2,550 | 2,607 |
Cash Flow and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Mn) | 4,346 | -1,309 | -16,238 | -7,120 | 6,636 |
Capital expenditure (KRW Mn) | -7,619 | -30,676 | -4,452 | -1,977 | -2,121 |
Free cash flow (KRW Mn) | -3,273 | -31,985 | -20,691 | -9,097 | 4,515 |
Capex as % of revenue (%) | 23.3 | 82.3 | 13.6 | 4.8 | 4.5 |
Dividends paid (KRW Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (KRW Mn) | 0 | 0 | 0 | -997 | -998 |
Net debt issued / repaid (KRW Mn) | 19,066 | 21,934 | 32,806 | 1,987 | -4,491 |
Investing cash flow (KRW Mn) | -7,757 | -26,399 | -1,978 | -9,841 | 6,183 |
Financing cash flow (KRW Mn) | 19,279 | 21,929 | 33,022 | 762 | -5,489 |
Cash interest paid (KRW Mn) | 413 | 836 | 1,851 | 2,016 | 1,661 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Return on equity (%) | 17.59 | 0.15 | -19.33 | -30.59 | -4.74 |
Return on assets (%) | 3.75 | 0.46 | -3.98 | -3.80 | -2.76 |
Return on invested capital (%) | 13.03 | 1.55 | -13.19 | -12.87 | -8.99 |
Current ratio (x) | 0.83 | 0.83 | 0.86 | 0.72 | 0.57 |
Quick ratio (x) | 0.77 | 0.64 | 0.62 | 0.50 | 0.44 |
Debt to equity (x) | 0.65 | 1.11 | 1.28 | 1.83 | 1.96 |
Net debt to equity (x) | -0.03 | 0.41 | 0.43 | 0.89 | 1.08 |
Interest coverage, EBIT/interest (x) | 5.56 | 0.40 | -2.30 | -1.69 | -1.09 |
Asset turnover (x) | 0.42 | 0.35 | 0.24 | 0.29 | 0.35 |
Days sales outstanding (days) | 64.9 | 72.0 | 59.9 | 69.4 | 67.5 |
Days inventory outstanding (days) | 11.1 | 65.4 | 141.3 | 138.9 | 63.9 |
Days payables outstanding (days) | 13.4 | 11.5 | 6.4 | 6.3 | 6.1 |
Cash conversion cycle (days) | 62.6 | 125.9 | 194.8 | 202.0 | 125.3 |
Geographic Revenue
| Indicator | Value | Period | Source |
|---|---|---|---|
KPrime revenue from US & Europe | ~50% | FY2025 | Company letter, Feb 2026 |
KPrime new contracts from overseas clients |
| H1 2026 | BizWatch, Aug 2026 |
KPrime 2026 target: overseas share of orders |
| FY2026 target | KPrime CEO Kim Dong-il, Feb 2026 |
Parent US/EU nonclinical order intake | Expected ~3x FY2025 (+200%) | FY2026 guidance | Company, Sep 2026 |
Parent overseas client base | Historically Japan-led; now diversifying to US, Europe, Singapore | 2026 | Company, Sep 2026 |
Regulatory submissions using group data | 25 (18 overseas INDs, 7 NDA/BLA) | 2023 – Sep 2026 | Company, Sep 2026 |
Share Price and Market Valuation
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (KRW) | 8,020 | 8,140 | 6,160 | 3,335 | 2,815 |
Market capitalisation (KRW Mn) | 117,384 | 119,140 | 98,113 | 52,429 | 44,254 |
Enterprise value (KRW Mn) | 118,446 | 128,169 | 127,342 | 78,212 | 75,280 |
Price / sales (x) | 3.59 | 3.20 | 3.01 | 1.27 | 0.94 |
Price / book (x) | 2.81 | 2.69 | 2.03 | 1.52 | 1.39 |
EV / sales (x) | 3.62 | 3.44 | 3.90 | 1.89 | 1.60 |
Market cap growth (%) | -47.09 | 1.50 | -17.65 | -46.56 | -15.59 |
Share Price & Returns
| Window | Return | Basis |
|---|---|---|
Year-to-date (from KRW 2,815 at FY2025 close) | ≈ −26% | Analyst calculation |
Since FY2023 close (KRW 6,160), ≈2.8 years | ≈ −66% | Analyst calculation; proxy for 3-year |
Since FY2021 close (KRW 8,020), ≈4.8 years | ≈ −74% | Analyst calculation; proxy for 5-year |
52-week range | KRW 1,896 – 4,115 | Investing.com / StockHub |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends paid FY2021–FY2025; none currently (Stockopedia) |
Buybacks | ~KRW 997M (FY2024); ~KRW 998M (FY2025, trust 27 Aug 2025 – 26 Feb 2026) |
Policy | Management has stated intent to pursue buybacks including cancellation (Feb 2026) |
Treasury ratio | ~3.46% |
Capital Markets — Short-term borrowings
| Item | KRW Mn | Notes |
|---|---|---|
Short-term borrowings | 53,493 | Bank lines; refinanced on a rolling basis (TTM issued KRW 14.4bn / repaid KRW 13.8bn) |
Current portion of long-term debt | 5,000 | Due within 12 months |
Long-term debt | 9,550 | Maturities not disclosed |
Leases | 316 | Current KRW 192M + long-term KRW 124M |
Total debt | 68,359 | — |
Cash and short-term investments | 29,255 | Includes KRW 4.4bn of trading securities |
Analyst Conclusions
Management guidance (qualitative):
-
FY2026 is the turnaround year.
-
Parent standalone operating profit in H2 2026 is described as highly likely.
-
KPrime operating profit is expected to widen from Q3 2026, with a full-year profit described as likely.
-
KPrime targets FY2026 order intake above KRW 30bn, with more than half from overseas.
-
US/EU orders at the parent are guided at about 3x FY2025.
Consensus: no active sell-side consensus.
Implied run-rate. H1 2026 revenue of KRW 26.3bn, plus backlog conversion, suggests FY2026 revenue in the mid-KRW 50bn range. This is analyst extrapolation, not guidance.
Bull case
-
Backlog converts with operating leverage. Group backlog of KRW 60.7bn exceeds a year of revenue, and SG&A is flat at ~KRW 8.8bn. Every KRW 10bn of added revenue at a mid-20s gross margin would add roughly KRW 2.5bn to EBIT, which would push the group to operating breakeven or better in FY2027.
-
KPrime becomes a profitable export franchise. It posted its first operating profit in Q2 2026, over 60% of H1 contracts were overseas, and primate capacity is scarce globally. A successful KOSDAQ IPO could recapitalise the subsidiary, eliminate the negative NCI and revalue the parent's stake well above the current KRW 32.7bn group market cap.
-
Modality mix lifts margins. The pivot to ADC/ASO/gene-therapy studies and turn-key SEND packages raises contract size and margins. Rising US/EU audit activity points to further export wins.
Bear case
-
Balance sheet outruns the recovery. Current liabilities of KRW 97bn against current assets of KRW 52.5bn, D/E of 3.05x and interest of about KRW 5.4bn per year leave little margin for error. Successive CB refinancings risk serial dilution at depressed prices.
-
Parent business remains structurally weak. Standalone revenue grew only 8% in H1 2026 in a domestic market marked by low-price competition and client credit stress. FY2025 profitability relied on one-off investment gains.
-
Turnaround has been announced before. The share price has fallen about 74% since the FY2021 close despite repeated recovery messaging. Investment-gain volatility (G2GBIO) and minority-interest accounting obscure underlying earnings. A slip in the Q3/Q4 2026 profit milestones would test credibility further.
Key catalysts and monitorables (next 12 months)
-
Q3 2026 results (mid-Nov 2026): parent standalone operating profit; KPrime margin progression.
-
Terms of the August 2026 CB (size, conversion price, refixing floor, put options) and the related large-shareholding filing.
-
KPrime IPO timeline: preliminary review filing with the Korea Exchange.
-
FY2026 order intake versus the KPrime KRW 30bn target and the parent's US/EU 3x guidance.
-
Short-term debt rollover and any equity raise.
-
G2GBIO stake valuation and any realisation.
-
Celltrion's holding: any change to the ~10.22% stake.
-
Any new FDA/OECD inspection outcome or GLP certification extension.
Analyst verdict
Biotoxtech is a credentialed but financially strained national toxicology champion in the middle of an operational turnaround. The operating evidence of 2026 is real:
-
H1 consolidated revenue rose 26%.
-
The operating loss narrowed by about 40%.
-
KPrime reached its first quarterly profit.
-
Group backlog stands at a record KRW 60.7bn.
-
The client base is shifting decisively towards US and European biotechs working on advanced modalities, where Korea-based NHP capacity and FDA-inspected GLP data are genuinely differentiated.
The asset base is largely in place after the KRW 30bn-plus 2022 build-out. With SG&A flat for three years, incremental revenue should carry high drop-through.
The equity story, however, is dominated by the capital structure rather than the operations:
-
Consolidated debt of KRW 68bn sits against roughly KRW 22bn of total equity.
-
Working capital is deeply negative.
-
A subsidiary with KRW 27.5bn of CBs depends on parent support.
-
The 2021 CB has just matured into a new CB issue.
The FY2025 return to attributable profit was an artefact of investment gains, and the TTM attributable result has slipped back to a KRW 4.0bn loss. Equity holders therefore face a race between EBITDA recovery and dilutive refinancing.
At about 0.6x sales and roughly 1x tangible book, the market is pricing a high probability that the race is lost or that value accrues mainly to mezzanine and KPrime minority holders. The upside case requires three things in sequence:
-
Sustained positive EBITDA from H2 2026.
-
A KPrime IPO that recapitalises the subsidiary on terms accretive to the parent.
-
No further deep-discount CB issuance.
Overall assessment: speculative recovery situation. The operating thesis is improving but the balance-sheet risk is high. The Q3 2026 standalone profitability print and the August 2026 CB terms are the two data points that should determine conviction. Investors and counterparties should complete diligence on the DART annual report (risk factors, related-party transactions, KPrime ownership) before relying on this assessment.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Kang Jong-koo (강종구) | Chairman & CEO (대표이사 회장), Biotoxtech; Chairman of KPrime Research | Founder, since 2000 | BVM and MS, Seoul National University; PhD, University of Tokyo graduate school. Formerly at a Japanese safety-evaluation research institute (named "Hypox" in Korean transliteration in the IR deck). Professor, College of Veterinary Medicine, Chungbuk National University (as of 2018) | Not publicly disclosed. Korean rules require individual disclosure only above KRW 500M |
Lee Byung-kyu (이병규) | Co-CEO at IPO (2007) | — | — | — |
Kim Dong-il (김동일) | CEO, KPrime Research | Since at least 2022 | — | — |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Event |
|---|---|
Early 2026 | First round of on-market share purchases by senior executives |
Aug 2026 | Second "relay" round: CEO Kang bought the same number of shares as each participating executive, framed as accountability and confidence in recovery (Money Today, 10 Aug 2026) |
26 Aug 2026 | Filing of an executive/major-shareholder specific-securities ownership report and a large-shareholding (5%+) report. |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
Kang Jong-koo and related parties | 15.96% (2,324,616 shares) | 30 Apr 2018 | 2018 IR deck |
Kang Jong-koo (individual) | 13.98% | H1 2018 | Dailypharm, Oct 2018 |
Celltrion Inc. | 11.20% (1,631,134 shares) | 30 Apr 2018 | 2018 IR deck |
Celltrion Inc. | ~10.22% | Feb 2026 | Company letter via BizWatch / Herald |
Treasury shares | ~3.46% | 2026 | Butler.works |
Other / free float | Remainder | — | — |
Competitive Landscape
Key Competitors
| Competitor | Type / domicile | Overlap with Biotoxtech | Relative positioning |
|---|---|---|---|
Korea Institute of Toxicology (KIT, 안전성평가연구소) | Government-funded research institute, Korea | GLP toxicology including NHP | Largest domestic public-sector rival; subsidised capacity |
Dt&CRO (디티앤씨알오, KOSDAQ 383930) | Listed CRO, Korea | Efficacy and GLP toxicology; nonclinical-to-Phase-1 full service | Differentiates on full service from nonclinical through Phase 1; revenue mix shifting towards clinical |
Chemon (켐온) | Private / Korea | GLP toxicology | Direct domestic toxicology rival |
Kolmar BioTech (formerly Woojung Bio) | Listed, Korea | Nonclinical efficacy CRO; pivoting to cosmetics safety CRO | Loss-making peer (H1 2025: revenue KRW 15.4bn, operating loss KRW 3.0bn) |
Knotus (노터스) | Korea | Efficacy studies | Niche efficacy competitor |
Charles River Laboratories | Global, US | Full nonclinical including NHP | — |
Labcorp (early development) | Global, US | Nonclinical toxicology | Global major |
Inotiv | US | Nonclinical toxicology, research models | Mid-size US competitor |
WuXi AppTec / Pharmaron / JOINN Laboratories | China | Nonclinical toxicology including NHP | Price-competitive Asian rivals with large primate capacity |
Shin Nippon Biomedical Laboratories (SNBL) | Japan | NHP toxicology | Competes for Japanese and global primate work |
Peer Comparison FY2025
| Metric | Biotoxtech (FY2025) | Biotoxtech (H1 2026) | Kolmar BioTech / Woojung Bio (H1 2025) |
|---|---|---|---|
Revenue | KRW 47.0bn | KRW 26.3bn | KRW 15.4bn |
Revenue growth | +13.7% | +26% | — |
Operating margin | −12.6% | ~−7.6% | ~−19.6% |
R&D intensity | 1.4% | — | — |
“—” = not publicly disclosed.
Recent Developments
All identifiable material items are listed; dates are publication or filing dates.
Not identified in the period: * litigation, regulatory sanctions, layoffs, guidance withdrawals or CEO changes.



